¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"plasma cell hepatitis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º¼¼Æ÷´Ü¹éÁú
  • cytotoxic killer T cell
    ¼¼Æ÷µ¶¼º»ìÇØT¼¼Æ÷
  • cell
    ¼¼Æ÷
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ
  • cell agar plate
    ¼¼Æ÷¿ì¹«ÆòÆÇ
  • cell bank
    ¼¼Æ÷ÀºÇà
  • cell body
    ¼¼Æ÷ü
  • cell color ratio
    ÀûÇ÷±¸»ö¼Òºñ
  • cell culture
    ¼¼Æ÷¹è¾ç
  • cell cycle
    ¼¼Æ÷ÁÖ±â
  • cell death
    ¼¼Æ÷»ç
  • cell dedifferentiation
    ¼¼Æ÷Å»ºÐÈ­
  • cell division
    ¼¼Æ÷ºÐ¿­
  • cell envelope
    ¼¼Æ÷²®Áú, ¼¼Æ÷ÇǸ·
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • cell organelle
    ¼¼Æ÷¼Ò±â°ü
  • cell respiration
    ¼¼Æ÷È£Èí
  • cell strain
    ¼¼Æ÷ÁÖ
  • cell substitution
    ¼¼Æ÷´ëÄ¡, Ç÷±¸´ëÄ¡
  • cell swelling
    ¼¼Æ÷Á¾Ã¢
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ
  • cell agar plate
    ¼¼Æ÷¿ì¹«ÆòÆÇ
  • cell color ratio
    ÀûÇ÷±¸»ö¼Òºñ
  • cell labeling technique
    ¼¼Æ÷Ç¥Áö±â¹ý
  • cell membrane permeability
    ¼¼Æ÷¸·Åõ°ú¼º
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cell-associated virus
    ¼¼Æ÷ºÎÂø¹ÙÀÌ·¯½º
  • cell-mediated cytolysis
    ¼¼Æ÷¸Å°³¼¼Æ÷¿ëÇØ
  • cell-mediated cytotoxicity
    ¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • cell-mediated hypersensitivity
    ¼¼Æ÷¸Å°³°ú¹Î
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • plasma turnover
    Ç÷À屳ü(úìíìÎßôð)
  • plasma volume
    Ç÷Àå·®(úìíìåÖ).
  • platelet rich plasma
    Ç÷¼ÒÆÇdzºÎÇ÷Àå
  • pooled blood plasma
    È¥ÁÖÇ÷Àå(ûèñ¬úìíì).
  • pooled blood plasma
    È¥ÁÖÇ÷Àå(ûèñ¬úìíì)
  • random plasma glucose test
    ÀÓÀÇ(Àû)Ç÷Àå´ç½ÃÇè
  • rapid plasma reagin card test
    RPRÄ«µå°Ë»ç
  • renal plasma clearance
    ½ÅÇ÷Àåû¼ÒÀ²(ãìúìíìôèá·ëÒ).
  • renal plasma flow
    ½ÅÇ÷ÀåÀ¯Åë·®(ãìúìíìêü÷×åÖ).
  • renal plasma flow
    ½ÅÇ÷Àå·ù(·®)
  • A cell
    A ¼¼Æ÷
  • B cell
    B¼¼Æ÷(~ á¬øà)
  • B cell
    B ¼¼Æ÷
  • B cell
    B ¼¼Æ÷.
  • B cell antigen
    B ¼¼Æ÷Ç׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • plasma
    Ç÷Àå(úìíì), ÇöóÁ.
  • plasma analysis
    Ç÷ÀåºÐ¼®
  • plasma clot
    Ç÷À屫.
  • plasma clot
    Ç÷À屫(úìíìÎÔ)
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • plasma component transfusion
    Ç÷À强ºÐ¼öÇ÷
  • plasma concentration
    Ç÷Àå³óµµ.
  • plasma cross matching
    Ç÷Àå±³Â÷½ÃÇè(úìíìÎßó©ãËúÐ).
  • plasma exchange
    Ç÷À屳ȯ
  • plasma exchange
    Çö󽺸¶±³È¯(¡­Îßüµ)
  • plasma exchange = plasmapheresis
    Ç÷À屳ȯ, Ç÷À强ºÐäÁý¼ú
  • plasma expander =p. volume e.
    ´ë¿ëÇöóÁ<Ç÷Àå>, ÇöóÁ<Ç÷Àå(úìíì )>Áõ·®Á¦(¡­ñòåÖð¥).
  • plasma factor
    Ç÷ÀåÀÎÀÚ(úìíìì×í­), ÇöóÁÀÎÀÚ.
  • plasma factor
    Ç÷ÀåÀÎÀÚ(úìíìì×í­), ÇöóÁÀÎÀÚ(¡­ì×í­)
  • plasma globulin
    ÇöóÁ±Û·ÎºÒ¸°, Ç÷Àå±Û·ÎºÒ¸°.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • Central glial cell
    ÁßÃ߾Ʊ³¼¼Æ÷
    [¿¾ ¿ë¾î] Á߽ɽŰ汳¼¼Æ÷
  • Glial cell of central nervous system
    ÁßÃ߾Ʊ³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁßÃß±³¼¼Æ÷
  • Mesothelial cell
    ÁßÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ÁßÇǼ¼Æ÷
  • Cuticular cell
    Áý²®Áú¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÇǼ¼Æ÷
  • Fenestrated endothelial cell
    â³»ÇǼ¼Æ÷
    [¿¾ ¿ë¾î] À¯Ã¢³»ÇǼ¼Æ÷
  • Interdental cell
    û°¢Ä¡¾Æ»çÀ̼¼Æ÷
    [¿¾ ¿ë¾î] ûġ°£¼¼Æ÷
  • Merkel`s cell
    Ã˰¢¼¼Æ÷
    [¿¾ ¿ë¾î] MerkelÃ˰¢¼¼Æ÷
  • Macula densa cell
    Ä¡¹Ð¹ÝÁ¡¼¼Æ÷
    [¿¾ ¿ë¾î] Ä¡¹Ð¹Ý¼¼Æ÷
  • Chromaffin cell
    ģũ·Ò¼¼Æ÷
    [¿¾ ¿ë¾î] Å©·Òģȭ¼¼Æ÷
  • Golgi cell
    Å«º°¼¼Æ÷
    [¿¾ ¿ë¾î] °ñÁö¼¼Æ÷
  • Large cell part
    Å«¼¼Æ÷ºÎºÐ
    [¿¾ ¿ë¾î] ´ë¼¼Æ÷ºÎ
  • Decidual cell
    Å»¶ô¸·¼¼Æ÷
    [¿¾ ¿ë¾î] Å»¶ô¸·¼¼Æ÷
  • Cuticular cell
    Åв®Áú¼¼Æ÷
    [¿¾ ¿ë¾î] ¸ð¼ÒÇǼ¼Æ÷
  • Matrix cell
    ÅйÙÅÁÁú¼¼Æ÷
    [¿¾ ¿ë¾î] ¸ð±âÁú¼¼Æ÷
  • Hair cell
    Åм¼Æ÷
    [¿¾ ¿ë¾î] À¯¸ð°¨°¢¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
CAH   1) Chronic Active Hepatitis
  2) Congenital Adrenal Hyperplasia
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
CLH Chronic Lobular Hepatitis
CPH Chronic Persistent Hepatitis
CVH Chronic Viral Hepatitis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
HBV Hepatitis B
HepB Hepatitis B
HBs-Ag Hepatitis Bs-antigen
HBV Hepatitis B virus
HB Ag Hepatitis B Antigen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell,hydropic degeneration
    ¼öÆ÷¼º º¯¼º
  • cell-mediated cytotoxicity
    ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
    Ç×ü ȤÀº lym
  • cell-mediated hypersensitivity
    ¼¼Æ÷ ¸Å°³¼º °ú¹ÎÁõ
    TuberculinÇü Çdz» ¹ÝÀÀÀ» ´ëÇ¥·Î ÇÑ´Ù. ¼¼Æ÷¼º ¸é¿ª ¹ÝÀÀÀÇ ÇÑ ÇüÅÂ. Ç׿ø¿¡ ÀÇÇÏ¿© °¨ÀÛµÈ µ¿¹°ÀÇ Çdz»¿¡ ÀçÂ÷ Ç׿øÀ» ÁÖ»çÇÔÀ¸·Î½á ¼ö ½Ã°£À¸·ÎºÎÅÍ 36½Ã°£ ÈÄ¿¡ ¹ßÀû, °æ°áÀ» ¼ö¹Ý½ÃŰ´Â Á¾Ã¢ÀÌ ÁÖ»ç ºÎÀ§¿¡ ¹ß»ýÇÏ´Â ¹ÝÀÀÀÌ´Ù.
  • cell-mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª
  • cell-mediated immunodeficiency syndrome
    ¼¼Æ÷¼º ¸é¿ª °áÇÌ ÁõÈıº
  • central giant cell
    °ñ³» °Å´ë ¼¼Æ÷
  • central giant cell tumor
    Á߽ɼº °Å´ë ¼¼Æ÷ ¾ÏÁ¾
  • central pain transmission cell
    ÁßÃß¼º ÅëÁõ Àü´Þ ¼¼Æ÷, ÁßÃß µ¿Åë Àü´Þ ¼¼Æ÷
  • centroacinar cell
    ²Ê¸® Á᫐ ¼¼Æ÷, »ùÆ÷ Á᫐ ¼¼Æ÷
  • clear cell
    Åõ¸í ¼¼Æ÷
    ±¸°­ »óÇÇÀÇ Á¶Á÷ Ç¥º»¿¡¼­ ´Ù¸¥ »óÇÇ ¼¼Æ÷¿Í´Â ´Þ¸® ÇÙ ÁÖÀ§¿¡ Åõ¸íÇÑ Èı¤
  • clear cell acanthoma
    Åõ¸í ¼¼Æ÷ ±Ø¼¼Æ÷Á¾
  • clear cell hidradenoma
    Åõ¸í ¼¼Æ÷ ÇѼ±Á¾
  • clear cell sarcoma
    Åõ¸í ¼¼Æ÷ À°Á¾
  • cleared cell
    Åõ¸í ¼¼Æ÷
  • columnar cell carcinoma
    ¿øÁÖ ¼¼Æ÷ ¾ÏÁ¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
hepatitis C <virology> A form of viral hepatitis, previously referred to as nonA nonB hepatitis, is the most common form of blood transfusion acquired hepatitis. Transmission through sexual contact is considered rare. Risk factors include recent blood transfusion, IV drug abuse or occupational exposure to blood products. There is no specific treatment. There is a test for hepatitis C antibody which indicates prior exposure. Unlike hepatitis b there is no marker yet identifiable for those who suffer from chronic hepatitis C.
(27 Sep 1997)
hepatitis c antibodies Antibodies to the hepatitis c antigens including antibodies to envelope, core, and non-structural proteins.
(12 Dec 1998)
hepatitis c antigens Antigens of the virions of hepatitis c-like viruses, their surface, core, or other associated antigens.
(12 Dec 1998)
hepatitis c, chronic An inflammatory disease of the liver caused by hepatitis c virus lasting six months or more.
(12 Dec 1998)
hepatitis, chronic A collective term for a clinical and pathological syndrome which has several causes and is characterised by varying degrees of hepatocellular necrosis and inflammation. Specific forms of chronic hepatitis include autoimmune hepatitis (hepatitis, autoimmune), chronic hepatitis b (hepatitis b, chronic), chronic hepatitis c (hepatitis c, chronic), chronic hepatitis d (hepatitis d, chronic), indeterminate chronic viral hepatitis, cryptogenic chronic hepatitis and drug-related chronic hepatitis (hepatitis, chronic, drug-induced).
(12 Dec 1998)
hepatitis, chronic, drug-induced An inflammatory disease of the liver, lasting six months or more, and caused by an adverse drug effect. The adverse effect may result from a direct toxic effect of a drug or metabolite, or an idiosyncratic response to a drug or metabolite. The clinical and histological changes can mimic viral or autoimmune hepatitis.
(12 Dec 1998)
hepatitis c-like viruses A genus of flaviviridae causing parenterally-transmitted non-a, non-b hepatitis (hepatitis c) which is associated with transfusions and drug abuse. Hepatitis c virus is the type species.
(12 Dec 1998)
hepatitis contagiosa canis A disease of dogs, caused by canine adenovirus 1, and characterised by fever, depression, loss of appetite, vomiting, bloody diarrhoea, petechial haemorrhages in the gums, pale mucous membranes, and jaundice.
Synonym: hepatitis contagiosa canis, Rubarth's disease.
(05 Mar 2000)
hepatitis C virus A non-A, non-B RNA virus causing post-transfusion hepatitis; it appears to be a member of the family Flaviviridae.
(05 Mar 2000)
hepatitis D <virology> A rare form of viral transfusion hepatitis. A defective viral agent that occurs only in association with hepatitis B infection. The delta agent may also increase the severity of hepatitis B infection. Complications include chronic persistent hepatitis and fulminant hepatitis. A test known as anti-delta agent antibody is positive and used to confirm the diagnosis. Treatment is the same as for hepatitis B.
(27 Sep 1997)
hepatitis d, chronic Inflammatory disease of the liver caused by hepatitis d virus in conjunction with hepatitis b virus and lasting six months or more.
(12 Dec 1998)
hepatitis d, e, f, and g Lesser known (than hepatitis a, b, and c), the most significant of these seems to be type d, or the delta agent, which only causes disease in the presence of the hepatitis b virus.
(12 Dec 1998)
hepatitis delta <virology> Hepatitis delta is a severe form of hepatitis which arose recently. It is caused by a combination of the delta virus (a defective virus) and the virus which causes hepatitis B.
(09 Oct 1997)
hepatitis delta virus A defective virus, containing particles of RNA nucleoprotein in virion-like form, present in patients with acute hepatitis b and chronic hepatitis. Officially this is classified as a subviral satellite RNA (RNA, satellite).
(12 Dec 1998)
hepatitis D virus A small "defective" RNA virus, similar to viroids and virusoids, that requires the presence of hepatitis B virus for replication. The clinical course is variable but is usually more severe than other hepatitides.
Synonym: hepatitis delta virus.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
ÅëÇÕ°Ë»ö ¿Ï·á